Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16097664 | 1.00 | MAPT (0.51) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL11552647 | 0.88 | MAPT (0.48) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL20213764 | 0.86 | MAPT (0.49) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL20213762 | 0.86 | MAPT (0.49) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL21144523 | 0.85 | MAPT (0.52) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL30416885 | 0.85 | SMN1; SMN2 (0.43) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL16745722 | 0.85 | MAPT (0.59) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL31405642 | 0.85 | MAPT (0.59) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL6308419 | 0.85 | MAPT (0.59) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL14991078 | 0.84 | MAPT (0.50) | MAPTALDH1A1KDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3574326-B1 | DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT | PHILIP MORRIS PRODUCTS SA (CH) | 2025-03-19 | — | — | EP | claimed |
| EP-4388015-A1 | ANTIBODY AND ANTIGEN BINDING FRAGMENTS THEREOF | Philip Morris Products S.A. (CH) | 2024-06-26 | — | — | EP | claimed |
| US-20240159775-A1 | WASTEWATER-BASED EPIDEMIOLOGY METHODS FOR ASSESSING POPULATION HEALTH | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-05-16 | — | — | US | claimed |
| CN-117677639-A | Antibodies and antigen binding fragments thereof | 菲利普莫里斯生产公司 | 2024-03-08 | — | — | CN | claimed |
| CN-110462403-B | Diagnostic test for distinguishing smoking status of a subject | 菲利普莫里斯生产公司 | 2024-01-12 | — | — | CN | claimed |
| WO-2023021003-A1 | ANTIBODY AND ANTIGEN BINDING FRAGMENTS THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-02-23 | — | — | WO | claimed |
| US-20200141933-A1 | DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT | PHILIP MORRIS PRODUCTS S.A. (CH) | 2020-05-07 | — | — | US | claimed |
| EP-2976061-B1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD (BE) | 2019-10-16 | — | — | EP | claimed |
| WO-2018211126-A1 | DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT | PHILIP MORRIS PRODUCTS S.A. (CH) | 2018-11-22 | — | — | WO | claimed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | claimed |
| US-4002671-A | REDUCE SEBUM SECRETION ON SCALP OR SKIN | SOCIETE ANONYME DITE: L'OREAL (FR) | 1977-01-11 | — | — | US | claimed |
| EP-3574326-B1 | DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT | PHILIP MORRIS PRODUCTS SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| US-20240385186-A1 | ANTIBODY AND ANTIGEN BINDING FRAGMENTS THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240385186-A1 | ANTIBODY AND ANTIGEN BINDING FRAGMENTS THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-4151301-A | ANTISECRETORY | L'OREAL (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4002671-A | REDUCE SEBUM SECRETION ON SCALP OR SKIN | SOCIETE ANONYME DITE: L'OREAL (FR) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | MAPT 2882/4885ALDH1A1 610/4885KDM4E 2421/4885 |
| US-20240385186-A1 | ANTIBODY AND ANTIGEN BINDING FRAGMENTS THEREOF | PA2G4, FCGR2A, FCGR3B | MAPT 4090/4885ALDH1A1 1723/4885KDM4E 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.